Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 222.50p on 13-06-2025 at 18:30:05
Change 2.50p 1.1%
Buy 230.00p
Sell 215.00p
Buy / Sell FARN Shares
Last Trade: Buy 1,999.00 at 230.00p
Day's Volume: 26,381
Last Close: 230.00p
Open: 227.50p
ISIN: FI4000153309
Day's Range 230.00p - 230.00p
52wk Range: 89.00p - 265.00p
Market Capitalisation: £269m
VWAP: 224.34793p
Shares in Issue: 117m

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1,999 230.00p Suspected BUY Trade
16:35:21 - 13-Jun-25
Sell* 1,000 217.10p Ordinary
16:29:52 - 13-Jun-25
Buy* 5,000 224.00p Ordinary
16:27:04 - 13-Jun-25
Sell* 1 222.35p Ordinary
15:11:49 - 13-Jun-25
Buy* 4,381 228.00p Ordinary
11:21:59 - 13-Jun-25
Sell* 1,000 220.00p Ordinary
11:18:50 - 13-Jun-25
Sell* 1,500 223.1875p Ordinary
11:16:32 - 13-Jun-25
Sell* 750 223.1875p Ordinary
11:16:30 - 13-Jun-25
Sell* 750 223.1875p Ordinary
11:16:28 - 13-Jun-25
Sell* 5,000 222.10p Ordinary
11:15:07 - 13-Jun-25
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
13th Jun 2025 (Fri) 227.50 230.00 230.00 230.00 26,381
12th Jun 2025 (Thu) 227.50 227.50 227.50 227.50 1,882
11th Jun 2025 (Wed) 225.00 235.00 227.50 227.50 3,721
10th Jun 2025 (Tue) 217.50 225.00 217.50 225.00 4,458
9th Jun 2025 (Mon) 215.00 217.50 215.00 217.50 6,142
6th Jun 2025 (Fri) 215.00 215.00 215.00 215.00 5,058
5th Jun 2025 (Thu) 225.00 225.00 212.50 215.00 36,474
4th Jun 2025 (Wed) 230.00 225.00 221.00 225.00 7,456
3rd Jun 2025 (Tue) 250.00 250.00 230.00 230.00 56,966
2nd Jun 2025 (Mon) 262.50 265.00 250.00 252.50 47,656
30th May 2025 (Fri) 245.00 262.50 245.00 262.50 29,028
29th May 2025 (Thu) 245.00 245.00 245.00 245.00 1,119
28th May 2025 (Wed) 245.00 247.50 240.00 245.00 17,415
27th May 2025 (Tue) 235.00 228.00 228.00 228.00 7,918
26th May 2025 (Mon) 235.00 235.00 235.00 235.00 0
23rd May 2025 (Fri) 245.00 245.00 232.50 235.00 23,310
22nd May 2025 (Thu) 235.00 245.00 235.00 240.00 22,792
21st May 2025 (Wed) 222.50 223.00 223.00 223.00 26,450
20th May 2025 (Tue) 215.00 221.00 217.50 221.00 20,442
19th May 2025 (Mon) 215.00 215.00 215.00 215.00 5,153
16th May 2025 (Fri) 225.00 220.00 215.00 215.00 12,790
15th May 2025 (Thu) 225.00 225.00 225.00 225.00 10,197
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Regulatory News

Date Source Headline
3rd Mar 2025 12:05 pm RNS FDA Grants Orphan Drug Designation
28th Feb 2025 12:00 pm RNS Notice of Annual General Meeting
27th Feb 2025 7:30 am RNS Positive EMA Opinion on Orphan Drug Designation
27th Feb 2025 7:15 am RNS Annual Report 2024 published
27th Feb 2025 7:00 am RNS Financial Statement 1 January to 31 December 2024
19th Feb 2025 10:00 am RNS Notice of Financial Statement and Annual Report
14th Feb 2025 12:00 pm RNS Holding(s) in Company
11th Feb 2025 7:30 am RNS Change of Broker
6th Feb 2025 3:00 pm RNS Holding(s) in Company
6th Feb 2025 7:00 am RNS Results of Oversubscribed Placing
See more Faron Pharmaceuticals regulatory news

Faron Pharmaceuticals (FARN) Share News

IN BRIEF: Faron Pharmaceuticals appoints new chief business officer

21st May 2025 12:41

Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Appoints Ralph Hughes as chief business officer, effective from next Wednesday. Notes Hughes' prior experience as senior vice president at PharmaVentures, and his extensive experience in commercial due diligence, market access and the business development process. Adds that he will be part of the management team and the business development team. "We are delighted to have such an experienced pharmaceutical market access and strategic commercial development expert to join us as the new CBO", says Chief Executive Juho Jalkanen. "Ralph's proven track record in biopharma leadership and his experience align perfectly with our corporate development efforts and strategic growth initiatives." Read More

UK shareholder meetings calendar - next 7 days

14th Mar 2025 14:09

Read More

UK earnings, trading statements calendar - next 7 days

20th Feb 2025 14:16

Read More

Faron Pharmaceuticals raises EUR12 million from oversubscribed placing

6th Feb 2025 11:41

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More

IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab

10th Dec 2024 14:31

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value8,850.63
Change-34.29

Login to your account

Forgot Password?

Not Registered